HBK Investments L P grew its stake in shares of Allergan plc (NYSE:AGN) by 2,064.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 93,057 shares of the company’s stock after purchasing an additional 88,757 shares during the period. HBK Investments L P’s holdings in Allergan were worth $15,222,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently made changes to their positions in the company. Edgewood Management LLC boosted its stake in shares of Allergan by 24.3% during the 3rd quarter. Edgewood Management LLC now owns 4,445,924 shares of the company’s stock valued at $911,192,000 after purchasing an additional 869,248 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Allergan by 2.2% during the 4th quarter. Geode Capital Management LLC now owns 3,422,365 shares of the company’s stock valued at $558,625,000 after purchasing an additional 72,303 shares in the last quarter. Baupost Group LLC MA boosted its stake in shares of Allergan by 21.9% during the 3rd quarter. Baupost Group LLC MA now owns 2,964,203 shares of the company’s stock valued at $607,513,000 after purchasing an additional 531,600 shares in the last quarter. Parnassus Investments CA boosted its stake in shares of Allergan by 20.4% during the 4th quarter. Parnassus Investments CA now owns 2,161,833 shares of the company’s stock valued at $353,633,000 after purchasing an additional 365,914 shares in the last quarter. Finally, Epoch Investment Partners Inc. boosted its stake in shares of Allergan by 1.0% during the 3rd quarter. Epoch Investment Partners Inc. now owns 1,805,608 shares of the company’s stock valued at $370,060,000 after purchasing an additional 17,068 shares in the last quarter. 78.40% of the stock is currently owned by hedge funds and other institutional investors.
A number of brokerages have recently weighed in on AGN. Wells Fargo & Co set a $245.00 target price on shares of Allergan and gave the company a “buy” rating in a research note on Friday, January 5th. Credit Suisse Group set a $214.00 price objective on shares of Allergan and gave the stock a “buy” rating in a research note on Tuesday, December 19th. They noted that the move was a valuation call. Royal Bank of Canada set a $218.00 price objective on shares of Allergan and gave the stock a “buy” rating in a research note on Thursday, January 4th. Citigroup dropped their price objective on shares of Allergan to $215.00 and set a “buy” rating on the stock in a research note on Tuesday, January 9th. Finally, Vetr lowered shares of Allergan from a “strong-buy” rating to a “buy” rating and set a $187.73 price objective on the stock. in a research note on Wednesday, December 6th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and fifteen have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $225.03.
Allergan plc (NYSE:AGN) opened at $158.41 on Tuesday. The company has a current ratio of 1.16, a quick ratio of 1.06 and a debt-to-equity ratio of 0.38. Allergan plc has a twelve month low of $142.81 and a twelve month high of $256.80. The firm has a market cap of $54,790.00, a P/E ratio of -13.21, a PEG ratio of 1.11 and a beta of 1.29.
Allergan (NYSE:AGN) last released its quarterly earnings data on Tuesday, February 6th. The company reported $4.86 earnings per share for the quarter, beating the consensus estimate of $4.74 by $0.12. Allergan had a negative net margin of 26.32% and a positive return on equity of 8.43%. The firm had revenue of $4.33 billion during the quarter, compared to analysts’ expectations of $4.28 billion. During the same period in the previous year, the company earned $3.90 earnings per share. The firm’s quarterly revenue was up 12.0% on a year-over-year basis. analysts anticipate that Allergan plc will post 15.58 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, March 28th. Investors of record on Wednesday, February 28th will be given a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 1.82%. This is a positive change from Allergan’s previous quarterly dividend of $0.70. The ex-dividend date is Tuesday, February 27th. Allergan’s payout ratio is -24.02%.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.